Understanding whether we can prevent acute myeloid leukaemia
In this study, the team want to understand whether it is possible to prevent people from developing acute myeloid leukaemia.
Acute myeloid leukaemia (AML) is an aggressive type of leukaemia which has poor outcomes for adults. Professor Vassiliou has previously found that people with AML have cells in the blood that are ‘pre-leukaemic’ years before they are diagnosed with the condition. This means there may be a way to prevent the disease although it’s currently unclear how to do this.
In this project, the team will try and find ways to prevent these pre-leukaemic cells from progressing into full blown leukaemia. The most common form of AML is caused by a mutation in a gene called DNMT3A. When this gene is mutated, it causes others to compensate which causes cells to grow uncontrollably leading to AML.
The team want to identify if the gene DNMT3A is responsible for cells becoming ‘pre-leukaemic’ and whether they could intervene at this stage to stop other cells compensating for this mutation, preventing the development of AML.
If this work is successful, it could help create an entirely new approach to blood cancers – one that focuses on prevention before they become a serious problem. It could also mean individuals have milder treatments and would give everyone with AML the best possible chance of survival.